For health professionals: Tuberculosis (TB)
Find information on tuberculosis (TB) for health professionals.
On this page
What health professionals need to know about tuberculosis
TB is an infectious disease caused by the bacteria Mycobacterium tuberculosis.
Of the people who are infected:
- 5% will develop active TB disease within 18 to 24 months
- 95% will develop latent TB infection, of which:
- 90% will never develop active TB disease
- 5% will have a reactivation and develop active TB at any point after initial infection
TB usually affects the lungs, but may also affect other organs, such as the:
- lymph nodes
TB is a legally reportable disease in every province and territory. This means that cases must be reported to the corresponding provincial and territorial department of health.
There are 2 types of TB infection:
- latent TB infection
- active TB disease
Latent tuberculosis infection (LTBI)
There are 2 accepted tests for identification of latent TB infection, which include the:
- tuberculin skin test
- interferon gamma release assay
Preference and exceptions are outlined in the Canadian Tuberculosis Standards.
A tuberculin skin test is used to diagnosis latent TB infection. The skin test is conducted by:
- injecting a small amount of non-infectious TB protein under the surface of the patient's skin using a small needle
- measuring the patient's reaction 2 or 3 days after the test
If the patient is infected with TB, a skin reaction will occur within 48 to 72 hours. The spot where the needle was injected will develop an area of redness with possible hardening (induration).
The area of hardness (not redness) should be objectively measured with a ruler. A measurement of more than 5 mm could be considered a positive result.
Inform your patient if the test is positive or negative.
A positive skin test
If a patient has a positive test result, you may need to:
- investigate further to rule out a false positive
- do more tests to find out if the patient has active TB disease
- assess signs and symptoms suggestive of possible active TB disease
- assess patient risk factors
- order a chest X-ray
In the presence of symptoms or abnormal chest X-ray, sputum for acid-fast bacteria smear and culture should be taken.
A positive test can happen even if a patient does not have a latent TB infection. This can happen in people who have been:
- vaccinated with Bacille Calmette-Guérin vaccine (BCG)
- infected with other TB-like germs
A negative skin test
A negative test result can happen even if a patient has TB bacteria in their body. This can occur if they have:
- a weak immune system due to:
- an HIV infection
- active TB disease
- recently been infected by a person with active TB disease:
- it takes 3 to 8 weeks after exposure for the skin test to become positive
Blood test (interferon gamma release assay)
A blood test for latent TB infection is:
- not recommended for routine diagnosis of latent TB infection
- only used under special circumstances
Active tuberculosis disease
Testing for active TB is indicated:
There are 3 steps in diagnosing active TB disease:
- do a complete medical history and examination
- order a chest X-ray
- order laboratory tests
Every effort should be made to obtain a microbiological diagnosis.
In Canada, the standard testing algorithm for active TB includes the following tests:
- chest radiography
- chest radiography cannot provide a conclusive diagnosis on its own
- it should be followed by microbiological tests for TB
- sputum smear microscopy
- everyone with suspected TB should undergo testing with at least 3 concentrated fluorescent smears
- sputum specimens should be collected a minimum of 1 hour apart
- same-day collection may be considered to reduce patient drop-out
- mycobacterial culture and phenotypic drug sensitivity testing (DST)
- every specimen sent for smear microscopy should be set up for culture in 1 solid and 1 liquid medium
- culture results typically take 2 to 8 weeks
- phenotypic DST should be routinely performed for all first positive culture isolates obtained from each new TB case
- rapid molecular tests for DST should be reserved for patients with a high pretest probability of multi-drug-resistant TB
- nucleic acid amplification testing (NAAT)
- take at least 1 respiratory sample with Health Canada-approved or -validated in-house NAAT in all new, smear-positive cases
- NAAT may also be performed in smear-negative patients
Prevention in health care settings
The incidence of active TB in Canada is generally low. However, exposure to people with undiagnosed active respiratory TB disease does occur in health care settings.
All health care settings should have a TB management or infection prevention and control program in place.
In a health care setting, infectious individuals should be placed in private (isolation) rooms.
To dilute the concentration of contaminants in an isolation room, the room must:
- have adequate ventilation
- be at negative air pressure
The air from the isolation room must be directly exhausted to the outside.
Other additional precautions may be used, such as:
- ultraviolet germicidal irradiation
- high-efficiency particulate air (HEPA) filtration
When outside an airborne infection isolation room, masks should be worn by:
- people with suspected or confirmed respiratory TB
Antibiotic drugs can cure active TB disease. All patients with active TB in Canada should be treated initially with a regimen of:
- isoniazid (INH)
- rifampin (RMP)
- pyrazinamide (PZA)
- ethambutol (EMB)
If the isolate causing disease is fully susceptible to all first-line drugs:
- EMB can be stopped
- PZA should be given for the first 2 months
- after that, only INH and RMP are required for the remainder of therapy, usually for another 4 months
The Canadian Tuberculosis Standards can provide further guidance on the treatment of:
- pediatric TB
- drug-resistant TB
- HIV-associated TB
- extrapulmonary TB
Directly observed treatment:
- can ensure that 100% of prescribed doses are taken
- is a recommended approach for patients with risk factors for non-adherence
The standard regimen of first choice for treating latent TB infection is 9 months of daily self-administered INH. More information is provided in the Canadian Tuberculosis Standards.
Health professionals in Canada play a critical role in identifying and reporting cases of TB. See the surveillance of TB section for more information on surveillance in Canada.
For more information
- Health Canada's Strategy Against Tuberculosis for First Nations On-Reserve
- Health Canada's Monitoring and Performance Framework for Tuberculosis Programs for First Nations On-reserve
- Canadian Tuberculosis Standards 7th Edition
- Tuberculosis in Canada 2014 - Pre-release
- Tuberculosis: Drug Resistance in Canada 2014
- Mycobacterium tuberculosis complex: Pathogen safety data sheet - Infectious substances
- Committee to Advise on Tropical Medicine and Travel (CATMAT)
- Canada Communicable Disease Report
- Active Tuberculosis Case Report Form - New and Re-treatment Cases
(PDF format, 537 KB, 1 page)
- Canadian Tuberculosis and Air Travel Reporting Form
(PDF format, 180 KB, 1 page)
- Treatment Outcome of a New Active or Re-treatment Tuberculosis Case
(PDF format, 372 KB, 1 page)
- M. Tuberculosis Complex Antimicrobial Susceptibility Reporting Form
(PDF format, 550 KB - 1 page)
Report a problem or mistake on this page
- Date modified: